Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (ARCT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
arct · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Arcturus Therapeutics Holdings Inc. (ARCT) measures how much investors pay for each dollar of the company's trailing earnings. ARCT's current PE ratio of N/A is calculated by dividing its stock price of $7.12 by its TTM earnings per share of -$2.77.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Arcturus Therapeutics Holdings Inc.You ARCT | $202M | N/A | — | -$2.77 |
 Achieve Life Sciences, Inc. ACHV | $563M | N/A | — | -$1.25 |
 Atea Pharmaceuticals, Inc. AVIR | $346M | N/A | — | -$1.94 |
 Foghorn Therapeutics Inc. FHTX | $218M | N/A | — | -$1.18 |
 Humacyte, Inc. HUMA | $232M | N/A | — | -$0.26 |
 Immuneering Corporation IMRX | $143M | N/A | — | -$1.27 |
 Sagimet Biosciences Inc. SGMT | $214M | N/A | — | -$1.58 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.40 | — | |
2024-12-31 FY2024 | — | $-3.00 | — | |
2023-12-31 FY2023 | — | $-1.12 | — | |
2022-12-31 FY2022 | 47.97x | $0.35 | — | |
2021-12-31 FY2021 | — | $-7.74 | — | |
2020-12-31 FY2020 | — | $-3.55 | — | |
2019-12-31 FY2019 | — | $-2.15 | — | |
2018-12-31 FY2018 | — | $-2.16 | — | |
2017-12-31 FY2017 | — | $-3.53 | — | |
2016-12-31 FY2016 | — | $-6.25 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Arcturus Therapeutics Holdings Inc. (ARCT) measures how much investors pay for each dollar of the company's trailing earnings. ARCT's current PE ratio of N/A is calculated by dividing its stock price of $7.12 by its TTM earnings per share of -$2.77.
Frequently asked questions
ARCT pe ratio · 6 questionsARCT's current PE ratio is N/A as of 2026-06-08, based on a stock price of $7.12 and TTM EPS of -$2.77. Data sourced from Financial Modeling Prep via ARCT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Arcturus Therapeutics Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08